Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Cort...

Descripción completa

Detalles Bibliográficos
Autores principales: Biemans, Vince B. C., Sleutjes, Jasmijn A. M., de Vries, Annemarie C., Bodelier, Alexander G. L., Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A., van der Meulen‐de Jong, Andrea E., de Boer, Nanne K. H., Srivastava, Nidhi, West, Rachel L., Römkens, Tessa E. H., Horjus Talabur Horje, Carmen S., Jansen, Jeroen M., van der Woude, C. Janneke, Hoekstra, Jildou, Weersma, Rinse K., van Schaik, Fiona D. M., Hoentjen, Frank, Pierik, Marieke J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Tofacitinib for Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187329/
https://www.ncbi.nlm.nih.gov/pubmed/32237087
http://dx.doi.org/10.1111/apt.15689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187329/
https://www.ncbi.nlm.nih.gov/pubmed/32237087
http://dx.doi.org/10.1111/apt.15689

Ejemplares similares